Insiders have done their cost/benefit analysis and
Post# of 573
Insiders have done their cost/benefit analysis and have been purchasing shares very actively over the past few months. Buying by insiders should never be taken lightly as they are normally privileged to more information than the public and are usually bound by 6-month lock-up periods and other SEC selling rules . Therefore, the fact that insiders are buying into the trend only adds more clout to my current and future bullish sentiment opinion. The recent insider buying details along with share and market value totals are detailed below.
Date | Name | Shares | Value |
12/18/2012 | Gregory L. Weaver MBA, CPA Chief Financial Officer & Senior Vice President | 8,636 | 23,921 |
12/10/2012 | Max E. Link, PhD Director | 14,000 | 106,400 |
12/7/2012 | Michael H. Tardugno President & Chief Executive Officer | 17,271 | 47,840 |
12/5/2012 | Alberto R. Martínez, MD Director | 34,583 | 112,394 |
11/15/2012 | Robert W. Hooper Director | 11,600 | 60,320 |
10/15/2012 | Alberto R. Martínez, MD Director | 2,500 | 5,900 |
10/15/2012 | Alberto R. Martínez, MD Director | 34,542 | 95,681 |
9/20/2012 | Max E. Link, PhD Director | 18,735 | 79,061 |
9/20/2012 | Max E. Link, PhD Director | 34,542 | 95,681 |
9/20/2012 | Max E. Link, PhD Director | 17,083 | 55,519 |
9/20/2012 | Max E. Link, PhD Director | 35,000 | 95,200 |
9/14/2012 | Michael H. Tardugno President & Chief Executive Officer | 1,900 | 9,576 |
9/14/2012 | Michael H. Tardugno President & Chief Executive Officer | 3,100 | 15,593 |
9/14/2012 | Jeffrey Wayne Church, CPA | 2,000 | 9,860 |
9/10/2012 | Robert W. Hooper Director | 3,491 | 17,280 |
9/10/2012 | Robert W. Hooper Director | 1,549 | 7,698 |
9/10/2012 | Robert W. Hooper Director | 3,800 | 18,848 |
9/10/2012 | Robert W. Hooper Director | 100 | 494 |
9/10/2012 | Robert W. Hooper Director | 1,060 | 5,215 |
8/29/2012 | Robert W. Hooper Director | 2,500 | 11,625 |
Totals: | 247,992 | $ 874,106.00 |
Pfizer ( PFE ) is early in the stages of creating a similar drug and as rumors suggest, is eying Celsion as a prospect for a partnership and eventually a future acquisition. A joint venture was actually signed with Pfizer on February 2012, so an indication of interest and relationships has been established. I know the first thought that comes to mind is possible share devaluation due to competition with Pfizer, an industry behemoth. This is a rational economic consideration, but within the short-term scope of bullish sentiment considered here, I doubt any significant competition will come from Pfizer as they are in the early stages and Celsion's Phase III results are just around the corner. Therefore, it may be better for Pfizer to partner with Celsion and 'piggyback' off their approval and eventually acquire the firm before their valuations increase. With that said, a partnership with or an acquisition by Pfizer would most likely occur after Phase III results come through and success is realized. Both a merger and acquisition would be bullish for CLSN, at least over the short run.
Market Sentiment - Open Interest on Options and Technical Indicators
Fundamental factors are great for defining the underlying strength or weakness of a company and the directional bias of a trend, but when it comes to entry and exit timing everything takes the back seat to technical analysis and sentiment indicators. Recently, CLSN options became available and a great tool for gauging the aggregate attitude of market participants is the change in open interest and volume figures of call and put options on the underlying stock. Since the scope of my analysis is over the short to intermediate-term, I focus on the January 19th and February 16th 2013 option expirations. As a quick refresher, options are contracts attached with the right but not the obligation to buy or sell 100 shares of the underlying stock at the issued strike price. For example, taking a long call position on CLSN with a strike price of 9 and expiration of January 19th 2013 (American Options), has the right but not the obligation to call 100 shares of the underlying stock away from the option writer (short party to the transaction) at the strike price any time before expiration. If expiration occurs and the underlying stock is below the call option strike price, then the option will expire worthless and the purchaser will be out the premium amount paid. The inverse is true for taking long positions in put options - the purchaser of these options pays a premium that allows them the right but not the obligation to "put" 100 shares of the underlying stock back to the writer of the option at the strike price any time before expiration. If the value is below the strike price before expiration, then the put option is in the money and the long party makes a gross profit.
As depicted below, both the January and February option contracts have volume and open interest. On the left hand side, Open interest corresponds to the call options at a given strike price. On the right side of the grid, open interest corresponds to put option contracts. After taking the net amount of open call and open put option interest at every strike price level and within each expiration month, you can see that the net amount increases from 9,854 to 16,871. This means that not only are there 9,854 open January call option contracts for every one put option contract, but the trend continues and increases into the February expiration - an increase of about 71%. This indicates that there are progressively more call option contracts being executed than put options, a bullish sign even if options are being used to hedge positions. Another interesting observation is the open interest of February calls at a $10 strike price; the amount of contracts is substantially higher than any other strike price level. This indicates the demand for contracts at this level and is actually the better bet for going long a call on CLSN.
Taking a long position in January 2013 calls would be too risky as this is the very month that the Phase III results are released and the risk of options expiring worthless due to regulatory delays is much greater than the reward in my opinion. Even though the premiums will be higher for February call options, it's worth the extra month to allow the market time to adjust and recalibrate to the results and any other developments. Furthermore, a $10 strike price is more optimal than say a $9 strike price as the further out of the money will offset a higher premium paid for a later expiration month. Since the Phase III results are truly a make it or break it situation, soaring above $10 dollars by February is not out of the question.
JAN 19 '13 | |||||
CALLS | PUTS | ||||
Open Interest | Volume | Strike Price | Volume | Open Interest | Net Open |
1,113.00 | 67.00 | 5.50 | 21.00 | 1,269.00 | (156.00) |
2,338.00 | 100.00 | 6.00 | 96.00 | 1,745.00 | 593.00 |
5,332.00 | 20.00 | 7.00 | 15.00 | 462.00 | 4,870.00 |
1,523.00 | 57.00 | 8.00 | 15.00 | 381.00 | 1,142.00 |
1,115.00 | 92.00 | 9.00 | 3.00 | 85.00 | 1,030.00 |
2,544.00 | 90.00 | 10.00 | - | 467.00 | 2,077.00 |
308.00 | 16.00 | 11.00 | - | 10.00 | 298.00 |
9,854.00 | |||||
FEB 16 '13 | |||||
CALLS | PUTS | ||||
Open Interest | Volume | Strike Price | Volume | Open Interest | Net Open |
184.00 | - | 5.50 | - | 181.00 | 3.00 |
888.00 | 63.00 | 6.00 | 225.00 | 2,527.00 | (1,639.00) |
4,436.00 | - | 7.00 | 16.00 | 800.00 | 3,636.00 |
3,314.00 | 637.00 | 8.00 | 5.00 | 1,896.00 | 1,418.00 |
1,015.00 | 167.00 | 9.00 | - | 55.00 | 960.00 |
11,402.00 | 186.00 | 10.00 | 58.00 | 232.00 | 11,170.00 |
1,333.00 | 83.00 | 11.00 | 10.00 | 10.00 | 1,323.00 |
16,871.00 |
*Independent research tools available at http://www.etrade.com (account required to generate data a/o 12/25/12)
The candlestick chart below helps to zoom in on the real-time market action and paints a picture of the psychological and economic forces at play. The sideways action that we are currently experiencing as portrayed in the daily chart below is due to the uncertainty and temporary equilibrium that buyers and sellers are in. Market participants have been waiting for the Phase III results that are due in January and much of the positioning ahead of this announcement has been entered into by long and short traders. Visually, this indifference ahead of Phase III results can be seen on the upper right hand "triangle" pattern. As the resistance and support levels of the triangle converge, the last two candlesticks to develop are what technical analyst refers to as Spinning Tops. The short length of these candles indicates and the open and close of that day was very close together - in other words, low volatility. Times of contracting price usually happen during low volume periods, as can be seen on the lower bar chart. Low volume reflects the market's steady-state as most news, up to now, has been ascertained and participants are waiting for results.
Prior to the lower volatility and indifference, the stock price had a dip, which I'm confident, was and still is a great buying or dollar cost averaging opportunity. From a technical analysis point of view, this dip was revealed many days before by a pattern on the chart known as technical divergence. Mapping the line connecting the tops of the volume candles from late November to Mid-December with the line directly above connecting the lows of the candlesticks reveals that volume began to decrease as price made higher highs - This simply means that price was losing momentum as buyers cashed out their positions. I'm confident the catalyst for this dip was is the anticipated increase in capital gains taxes, a component of the looming fiscal cliff set to take effect on the first of January. Long parties are up quite a bit and many desired to cash in on these profits at a lower tax rate.
Some considerations
Negative EPS and the large amount of short positions on CLSN have been the focus of motivated bears and many unsure bulls. Negative EPS on a medical company relying on Research & Development outflows to secure patents and pass regulatory hurdles is common; even more so with a company such as CLSN that has dipped much less into dilutive capital raising methods, with the exception of minimal equity financing initiatives.
With regards to the high amount of short positions on CLSN , I'm confident this will work in the bulls' favor after Phase III results are made public. Shorts are already experiencing drastic draw-downs as CLSN posts a YTD return of over 300%. Therefore, if investors are assumed to be rational then the majority of these short positions has corresponding stop-losses above their short entry price.These are called "covers" once executed and are effectively buy transactions. Once CLSN breaks out and above the tight range it's currently in and more confidence and directional bias enters the market, the short position stop-losses will be executed and only add bullish fuel to CLSN.
Business relationship disclosure : CenturyFX Group is a team of market analysts. This article was co-written by Armando Izaguirre & Michael Gentilella, managing partners at CenturyFX. We did not receive compensation for this article (other than from Seeking Alpha), and we have no business relationship with any company whose stock is mentioned in this article.